Drug profile · INN
clascoterone
WINLEVI
clascoterone (WINLEVI) is a androgen receptor antagonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — clascoterone
- US status
- approved
- Class
- Dermatologicals (D10)
- Route
- TOPICAL
- Patents
- 5
- Programs
- 4
- Data quality
- 0.84
Quick answer
clascoterone (WINLEVI) is a androgen receptor antagonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Androgen Receptor antagonist
Primary target: Androgen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025125508
COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ
granted -
WO 2025068281
CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES
granted -
EP 4529925
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
granted -
CA 2934118
PROPIONATE DE CORTEXOLONE-17' DESTINE A ETRE UTILISE DANS LE TRAITEMENT DE LESIONS CUTANEES ET/OU DE TROUBLES DE LA PEAU ATROPHIQUE
granted -
AU 2005207635
Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
expired
Frequently asked questions
What is clascoterone?
clascoterone (WINLEVI) is a androgen receptor antagonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for clascoterone?
WINLEVI is a marketed brand name for clascoterone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clascoterone?
clascoterone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.